European Vaccine Initiative to celebrate one-day symposium in Heidelberg

The European Vaccine Initiative (EVI) will celebrate a one-day symposium in Heidelberg surrounding global health and diseases of poverty on occasion of the 15th anniversary of EVI.

On 26 February 2013 the European Vaccine Initiative (EVI) will celebrate a one-day symposium in Heidelberg surrounding global health and diseases of poverty on occasion of the 15th anniversary of EVI. For the last one and half decade, EVI has supported the development of vaccines against malaria and other diseases of poverty by providing financial and operational-managerial support and by advocacy related to these causes.

The symposium is targeted in particular at representatives of policy makers, funding bodies (ministries, research councils, foundations/charities etc), industry, and researchers and other individuals with interest in global health issues. Renowned speakers from different public and private organisations will present their views on the topic from different angles, and an outlook on the future of these topics under the up-coming EU framework programme Horizon2020, including the renewed European & Developing Countries Clinical Trials Partnership (EDCTP II), will be provided.

The event is free of charge, registration is open for everyone. As space is limited, registrations are subject to approval.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Argonne receives $21.7 million to advance cancer and vaccine discoveries